FrancophonIA/ELRC3.0 huggingface dataset:
English: • high fever in combination with measles-like skin rash, enlarged lymph nodes, liver enlargement, hepatitis (up to liver failure), raising of the white-cells count in the blood (leukocytosis, with or without eosinophilia)
Slovenian: • Zvišana telesna temperatura v kombinaciji z noricam podobnimi kožnimi izpuščaji, povečani limfatični vozliči, povečanje jeter, hepatitis (vse do jetrne odpovedi), povečano število belih krvničk v krvi (levkociti, z ali brez eozinofilije).
English: If serum uric acid is > 6 mg/dL (357 µmol/L) after 2-4 weeks, ADENURIC 120 mg once daily may be considered.
Slovenian: Če je po 2-4 tednih koncentracija sečne kisline v serumu > 6 mg/dl (357 µmol/l), je smiselno razmisliti o jemanju zdravila ADENURIC v odmerku 120 mg enkrat na dan.
English: FLORENCE was a randomized (1:1), double blind, phase III, pivotal trial comparing ADENURIC 120 mg once daily with allopurinol 200 to 600 mg daily (mean allopurinol daily dose [± standard deviation]: 349.7 ± 112.90 mg) in terms of control of serum uric acid level.
Slovenian: V študiji FLORENCE, ki je bila randomizirana (1:1), dvojno slepa, pilotska študija 3. faze, so primerjali, kako zdravili ADENURIC 120 mg enkrat na dan in alopurinol 200 do 600 mg dnevno (povprečni dnevni odmerek alopurinola [± standardna deviacija]: 349,7 ± 112,90 mg), vplivata na serumske vrednosti sečne kisline.
English: 62% of patients required no dose adjustment to maintain sUA <6 mg/dL and 38% of patients required a dose adjustment to achieve a final stable dose.
Slovenian: Vključenih je bilo 116 bolnikov, ki so prejemalo prvotni odmerek febuksostat 80 mg enkrat na dan. 62 % bolnikov ni potrebovalo prilagajanja odmerka za vzdrževanje sUA < 6 mg/dl, 38 % bolnikov pa je potrebovalo prilagoditev odmerjanja, za dosego končnega ciljnega stabilnega odmerka.
English: ADENURIC is available as a 120 mg tablet.
Slovenian: Zdravilo ADENURIC je na voljo kot 120 mg tableta.
English: Patients should exercise caution before driving, using machinery or participating in dangerous activities until they are reasonably certain that ADENURIC does not adversely affect performance.
Slovenian: Po uporabi febuksostata so poročali o neželenih učinkih, kot so zaspanost, omotica, parestezija in zamegljen vid. Bolniki morajo biti pred vožnjo, uporabo strojev ali udeležbo v tveganih dejavnostih previdni, dokler niso povsem prepričani, da zdravilo ADENURIC ne vpliva negativno na opravljanje teh dejavnosti.
English: How to take ADENURIC
Slovenian: Kako jemati zdravilo ADENURIC
English: Mean AUC sUA1-8 (mgxh/dl) was significantly lower with ADENURIC (514.0 ± 225.71 vs 708.0 ± 234.42; least square means difference: -196.794 [95% confidence interval: -238.600 ; -154.988]; p < .0001).
Slovenian: Srednja AUC sUA1-8 (mgxh/dl) je bila značilno manjša pri uporabi zdravila ADENURIC (514,0 ± 225,71 proti 708,0 ± 234,42; razlika povprečne vrednosti najmanjšega kvadrata: -196,794 [95 % interval zaupanja: -238,600 ; -154.988]; p < 0,0001).
English: Cardiac disorders: Uncommon: Left bundle branch block, sinus tachycardia
Slovenian: Srčne bolezni: Občasni: levokračni blok, sinusna tahikardija
English: Dizziness, paraesthesia, hemiparesis, somnolence, altered taste, hypoaesthesia, hyposmia
Slovenian: Občasni omotica, parestezija, hemipareza, somnolenca, spremenjeno okušanje, hipestezija, zmanjšana sposobnost voha
English: Pale yellow to yellow, film-coated, capsule shaped tablets, engraved with “120” on one side
Slovenian: Svetlorumene do rumene, filmsko obložene tablete v obliki kapsule, ki imajo na eni strani vtisnjeno oznako »120«.
English: In the additional phase 3 CONFIRMS study, for which results became available after the marketing authorisation for ADENURIC was first issued, the primary efficacy endpoint was the proportion of patients whose serum urate level was < 6.0 mg/dL at the final visit.
Slovenian: V dodatni študiji 3. faze CONFIRMS, za katero so bili rezultati na voljo po prvi pridobitvi dovoljenja za promet z zdravilom ADENURIC, je bil primarni opazovani dogodek učinkovitosti delež bolnikov, pri katerih je bil nivo sečne kisline v serumu na končnem pregledu < 6,0 mg/dl. Bolniki s presajenimi organi niso bili vključeni v študiji (glejte poglavje 4.2).
English: ADENURIC works sufficiently quickly to allow retesting of the serum uric acid after 2 weeks.
Slovenian: Zaradi hitrega nastopa učinka zdravila ADENURIC se lahko preverjanje sečne kisline v serumu izvede že po 2 tednih.
English: labeled febuxostat, approximately 49% of the dose was recovered in the urine as unchanged febuxostat (3%), the acyl glucuronide of the active substance (30%), its known oxidative metabolites and their conjugates (13%), and other unknown metabolites (3%).
Slovenian: Po peroralnem odmerku 80 mg s 14C označenega febuksostata se je približno 49 % odmerka izločilo z urinom, 3 % v obliki nespremenjenega febuksostata, 30 % v obliki acil-glukuronida učinkovine, 13 % v obliki znanih oksidativnih presnovkov in njihovih konjugatov ter 3 % v obliki drugih neznanih presnovkov.
English: Rare serious hypersensitivity reactions to febuxostat, some of which were associated to systemic symptoms, and rare events of sudden cardiac death, have occurred in the post-marketing experience.
Slovenian: V obdobju trženja so poročali o redkih resnih preobčutljivostnih reakcijah na febuksostat, pri čemer so bile nekatere povezane s sistemskimi simptomi, in redkih dogodkih nenadne kardialne smrti.
English: The APEX Study evaluated efficacy in 40 patients with renal impairment (i.e., baseline serum creatinine > 1.5 mg/dL and ≤2.0 mg/dL).
Slovenian: Primarni opazovani dogodek v podskupini bolnikov z okvaro delovanja ledvic V študiji APEX je bila ocenjena učinkovitost pri 40 bolnikih z okvaro delovanja ledvic (tj. izhodiščna vrednost kreatinina v serumu > 1,5 mg/dl in ≤ 2,0 mg/dl).
English: Oral use ADENURIC should be taken by mouth and can be taken with or without food.
Slovenian: Zdravilo ADENURIC se jemlje peroralno, s hrano ali brez hrane.
English: MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS PVC/ACLAR/ALUMINIUM OR PVC/PE/PVDC/ALUMINIUM BLISTER
Slovenian: PVC/Aclar/aluminij ali PVC/PE/PVDC/aluminij pretisni omot
English: • stones in the gallbladder or in bile ducts (cholelithiasis)
Slovenian: • žolčni kamni v žolčniku in žolčnih vodih (holecistitis),
English: The FACT study showed the statistically significant superiority of both ADENURIC 80 mg and ADENURIC 120 mg QD treatment arms versus the conventionally used dose of allopurinol 300 mg treatment arm in reducing and maintaining sUA below 6 mg/dL (357 µmol/L).
Slovenian: Študija FACT je pokazala statistično pomembno prednost obeh oblik zdravljenja z zdravilom ADENURIC 80 mg in z zdravilom ADENURIC 120 mg enkrat na dan v primerjavi z običajno uporabljenim odmerkom alopurinola 300 mg pri zmanjšanju in vzdrževanju ravni sečne kisline v serumu pod 6 mg/dl (357 µmol/l).
English: The 80 mg film-coated tablets are marked on one side with ‘80' and on the other side with a score line.
Slovenian: 80 mg filmsko obložene tablete imajo na eni strani vtisnjeno oznako ‘80'.
English: Gout flares during the last 4 weeks of the study (Weeks 49-52) were observed in 6-8% (febuxostat 80 mg, 120 mg) and 11% (allopurinol 300 mg) of subjects.
Slovenian: Izbruhe protina so opazili tudi v zadnjih 4 tednih študije (tedni od 49 do 52) pri 6-8 % (febuksostat 80 mg, 120 mg) in 11 % (alopurinol 300 mg) oseb.
English: One thousand and seventy-two (1072) patients were randomized: placebo (n=134), ADENURIC 80 mg QD (n=267), ADENURIC 120 mg QD (n=269), ADENURIC 240 mg QD (n=134) or allopurinol (300 mg QD [n=258] for patients with a baseline serum creatinine ≤1.5 mg/dL or 100 mg QD [n=10] for patients with a baseline serum creatinine >1.5 mg/dL and ≤2.0 mg/dL).
Slovenian: Naključno je bilo razvrščenih tisoč dvainsedemdeset (1.072) bolnikov: placebo (n=134), zdravilo ADENURIC 80 mg enkrat na dan (n=267), zdravilo ADENURIC 120 mg enkrat na dan (n=269), zdravilo ADENURIC 240 mg enkrat na dan (n=134) ali alopurinol (300 mg enkrat na dan [n=258] za bolnike z izhodiščno vrednostjo kreatinina v serumu  1,5 mg/dl ali 100 mg enkrat na dan [n=10] za bolnike z izhodiščno vrednostjo kreatinina v serumu > 1,5 mg/dl in  2,0 mg/dl).
English: ADENURIC contains lactose
Slovenian: Zdravilo ADENURIC vsebuje laktozo
English: ADENURIC is available as either an 80 mg tablet or a 120 mg tablet.
Slovenian: Zdravilo ADENURIC je na voljo v obliki 80 mg tablet ali 120 mg tablet.
English: The common side effects (may affect up to 1 in 10 people) are:
Slovenian: Pogosti neželeni učinki (pojavijo se pri 1 od 10 bolnikov) so:
English: However, drug-drug and drug-disease interactions were not explored during this study.
Slovenian: Med študijo ni bilo opravljene raziskave o medsebojnem delovanju med zdravili ter med zdravilom in boleznijo.
English: Two hundred and forty mg febuxostat (2 times the recommended highest dose) was used as a safety evaluation dose.
Slovenian: Za ocenitev varnosti je bil uporabljen odmerek dvesto štirideset mg (240 mg) febuksostata (dvakratni najvišji priporočeni odmerek).
English: The APEX study showed statistically significant superiority of both the ADENURIC 80 mg QD and the ADENURIC 120 mg QD treatment arms versus the conventionally used doses of allopurinol 300 mg (n = 258) /100 mg (n = 10) treatment arm in reducing the sUA below 6 mg/dL (357 µmol/L) (see Table 2 and Figure 1).
Slovenian: Študija APEX je pokazala statistično pomembno prednost obeh oblik zdravljenja z zdravilom ADENURIC v odmerku 80 mg enkrat na dan in z zdravilom ADENURIC 120 mg enkrat na dan v primerjavi z običajno uporabljenim odmerkom alopurinola 300 mg (n=258) /100 mg (n=10) pri zmanjšanju koncentracije sečne kisline v serumu pod 6 mg/dl (357 µmol/l) (glejte tabelo 2 in sliko 1).
English: Gout flares during the last 4 weeks of the study (Weeks 24-28) were observed in 15% (febuxostat 80, 120 mg), 14% (allopurinol 300 mg) and 20% (placebo) of subjects.
Slovenian: Odstotki izbruhov protina pri preiskovancih v zadnjih 4 tednih študije (tedni od 24 do 28), so bili 15 % (febuxostat 80, 120 mg), 14 % (alopurinol 300 mg) in 20 % (placebo).
English: The recommended oral dose of ADENURIC is 80 mg once daily without regard to food.
Slovenian: Priporočeni peroralni dnevni odmerek zdravila ADENURIC je 80 mg enkrat na dan ne glede na uživanje hrane.
English: Gout: The recommended oral dose of ADENURIC is 80 mg once daily without regard to food.
Slovenian: Protin: Priporočeni peroralni dnevni odmerek zdravila ADENURIC je 80 mg enkrat na dan ne glede na uživanje hrane.
English: In this subgroup ADENURIC achieved the primary efficacy endpoint (sUA < 6.0 mg/dL at the last 3 visits) in 41% (80 mg QD), 48% (120 mg QD), and 66% (240 mg QD) of patients compared to 9% in the allopurinol 300 mg/100 mg QD and 0 % in the placebo groups.
Slovenian: V tej podskupini je bil primarni opazovani dogodek učinkovitosti (sUA < 6,0 mg/dl pri zadnjih treh pregledih) dosežen pri 41 % (80 mg enkrat na dan), 48 % (120 mg enkrat na dan) in 66 % (240 mg enkrat na dan) bolnikov v skupinah, ki je jemala zdravilo ADENURIC v primerjavi z 9 % v skupini, zdravljeni z alopurinolom 300 mg ali 100 mg enkrat na dan, in 0 % v placebo skupini.
English: In male rats, a statistically significant increase in urinary bladder tumours (transitional cell papilloma and carcinoma) was found only in association with xanthine calculi in the high dose group, at approximately 11 times human exposure.
Slovenian: Karcinogeneza, mutageneza, škodljivo delovanje na plodnost Pri podganjih samcih so opazili statistično pomembno večjo pojavnost tumorjev sečnega mehurja (prehodnocelični papilom in karcinom) samo v povezavi s ksantinskimi kamni pri skupini, ki je bila izpostavljena visokim odmerkom, približno 11-kratni izpostavljenosti človeka.
English: Vascular disorders: Uncommon: haemorrhage
Slovenian: Žilne bolezni: Občasni: hemoragija
English: There were no significant changes observed in AUC of febuxostat or its metabolites following multiple oral doses of ADENURIC in elderly as compared to younger healthy subjects.
Slovenian: Po večkratnih peroralnih odmerkih zdravila ADENURIC se AUC febuksostata ali njegovih presnovkov pri starostnikih ni pomembneje spremenila v primerjavi z mlajšimi zdravimi osebami.
English: No significant difference in mean serum creatinine change (%) occurred between ADENURIC and allopurinol (-0.83 ± 26.98 vs -4.92 ± 16.70 respectively; least square means difference: 4.0970 [95% confidence interval: -0.6467 ; 8.8406]; p=0.0903).
Slovenian: Srednja vrednost spremembe kreatinina pri zdravilu ADENURIC in alopurinolu ni bila pomembna (-0,83 ± 26,98 proti -4,92 ± 16,70; razlika povprečne vrednosti najmanjšega kvadrata: 4,0970 [95 % interval zaupanja: -0,6467 ; 8,8406]; p=0,0903).
English: Pale yellow to yellow, film-coated, capsule shaped tablets, engraved with “80” on one side and a score line on the other side.
Slovenian: Svetlorumene do rumene, filmsko obložene tablete v obliki kapsule, ki imajo na eni strani vtisnjeno oznako »80«.
English: Berlin-Chemie / A. Menarini Distribution Slovakia s.r.o
Slovenian: Slovenská republika Berlin-Chemie / A. Menarini Distribution Slovakia s.r.o
English: Lactose monohydrate Microcrystalline cellulose Magnesium stearate Hydroxypropylcellulose Croscarmellose sodium Silica, colloidal hydrated
Slovenian: Jedro tablete laktoza monohidrat mikrokristalna celuloza magnezijev stearat hidroksipropilceluloza premreženi natrijev karmelozat koloidni hidratirani silicijev dioksid
English: A total of 1,086 patients were enrolled: ADENURIC 80 mg QD (n=649), Adenuric 120 mg QD (n=292) and allopurinol 300/100 mg QD (n=145).
Slovenian: Skupaj je bilo vključenih 1.086 bolnikov in sicer: ADENURIC 80 mg enkrat na dan (n = 649), ADENURIC 120 mg enkrat na dan (n = 292) in alopurinol 300/100 mg enkrat na dan (n = 145).
English: Marketing Authorisation Holder: Menarini International O. L. S.A. 1, Avenue de la Gare, L-1611 Luxembourg Luxembourg
Slovenian: Menarini International O. L. S. A. 1, Avenue de la Gare, L-1611 Luxembourg Luksembourg
English: Rare serious hypersensitivity reactions to febuxostat, including Stevens-Johnson Syndrome, Toxic epidermal necrolysis and anaphylactic reaction/shock, have occurred in the post-marketing experience.
Slovenian: V obdobju trženja so se pojavile redke resne preobčutljivostne reakcije na febuksostat, vključno s Stevens-Johnsonovim sindromom, toksično epidermalno nekrolizo in anafilaktično reakcijo/šokom.
English: Allopurinol 100 mg QD1
Slovenian: Alopurinol 100 mg enkrat na dan1
English: ADENURIC 80 mg and 120 mg is available in packs containing 14, 28, 42, 56, 84 and 98 film-coated tablets.
Slovenian: Zdravili ADENURIC 80 mg in 120 mg sta na voljo v pakiranjih po 14, 28, 42, 56, 84 in 98 filmsko obloženih tabletah.
English: ADENURIC 120 mg is available in pack sizes of 14, 28, 42, 56, 84 and 98 film-coated tablets.
Slovenian: Zdravilo ADENURIC 120 mg je na voljo v škatlah po 14, 28, 42, 56, 84 in 98 filmsko obloženih tablet.
English: ADENURIC 80 mg is available in pack sizes of 14, 28, 42, 56, 84 and 98 film-coated tablets.
Slovenian: Zdravilo ADENURIC 80 mg je na voljo v škatlah po 14, 28, 42, 56, 84 in 98 filmsko obloženih tablet.
English: Febuxostat has been shown to potently inhibit both the oxidized and reduced forms of XO. At therapeutic concentrations febuxostat does not inhibit other enzymes involved in purine or pyrimidine metabolism, namely, guanine deaminase, hypoxanthine guanine phosphoribosyltransferase, orotate phosphoribosyltransferase, orotidine monophosphate decarboxylase or purine nucleoside phosphorylase.
Slovenian: Febuksostat v terapevtskih koncentracijah ne zavira drugih encimov, ki so udeleženi pri presnovi purina ali pirimidina, kot so gvanin deaminaza, hipoksantin gvanin fosforibozil transferaze, orotat fosforibozil transferaza, orotidin monofosfat dekarboksilaza ali purin nukleozid fosforilaza.
English: It is not known if ADENURIC may harm your unborn child. ADENURIC should not be used during pregnancy.
Slovenian: Ni znano, ali zdravilo ADENURIC škodljivo vpliva na nerojenega otroka.
English: EU/1/08/447/001 EU/1/08/447/002 EU/1/08/447/005 EU/1/08/447/006 EU/1/08/447/007 EU/1/08/447/008 EU/1/08/447/013 EU/1/08/447/014 EU/1/08/447/015
Slovenian: EU/1/08/447/001 EU/1/08/447/002 EU/1/08/447/005 EU/1/08/447/006 EU/1/08/447/007 EU/1/08/447/008 EU/1/08/447/013 EU/1/08/447/014 EU/1/08/447/015 EU/1/08/447/016 EU/1/08/447/017 EU/1/08/447/018
English: Rare reports of serious allergic/hypersensitivity reactions, including life-threatening Stevens-Johnson Syndrome, Toxic epidermal necrolysis and acute anaphylactic reaction/shock, have been collected in the post-marketing experience.
Slovenian: Izkušnje v obdobju po trženju kažejo, da so se redko pojavile resne alergijske/preobčutljivostne reakcije, vključno z življenjsko nevarnim Stevens-Johnsonovim sindromom, toksično epidermalno nekrolizo in akutno anafilaktično reakcijo/šokom.
English: Seven hundred sixty (760) patients were randomized: ADENURIC 80 mg QD (n=256), ADENURIC 120 mg QD (n=251), or allopurinol 300 mg QD (n=253).
Slovenian: Naključno je bilo razvrščenih sedemsto šestdeset (760) bolnikov: zdravilo ADENURIC 80 mg enkrat na dan (n=256), zdravilo ADENURIC 120 mg enkrat na dan (n=251) ali alopurinol 300 mg enkrat na dan (n=253).
English: Febuxostat can be co-administered with colchicine or indomethacin with no dose adjustment of febuxostat or the co-administered active substance being necessary.
Slovenian: Kolhicin/indometacin/hidroklorotiazid/varfarin Febuksostat se lahko daje sočasno s kolhicinom ali indometacinom brez prilagoditve odmerka febuksostata ali zdravilne učinkovine, ki se daje hkrati.
English: Two thousand and two hundred-sixty nine (2269) patients were randomized: ADENURIC 40 mg QD (n=757), ADENURIC 80 mg QD (n=756), or allopurinol 300/200 mg QD (n=756).
Slovenian: Skupno je bilo vključenih 2.269 bolnikov: ADENURIC 40 mg na dan (n=757), ADENURIC 80 mg na dan (n=756) ali alopurinol 300/200 mg na dan (n=756).
English: 6.0 mg/dL at the final visit) for patients with a baseline serum urate level of ≥ 10 mg/dL treated with febuxostat 40 mg QD was 27% (66/249), with febuxostat 80 mg QD 49% (125/254) and with allopurinol 300 mg/200 mg QD 31% (72/230), respectively.
Slovenian: V študiji CONFIRMS je bil delež bolnikov, pri katerih je bil dosežen primarni opazovani dogodek učinkovitosti (sUA < 6,0 mg/dl pri zadnjem pregledu) in z začetno vrednostjo sečne kisline ≥ 10 mg/dl, ki so bili zdravljeni z 40 mg febuksostata enkrat na dan 27 % (66/249), 80 mg febuksostata enkrat na dan 49 % (125/254) v primerjavi z 31 % (72/230) bolnikov zdravljenih z 300 mg/200 mg enkrat na dan alopurinola.
English: EU/1/08/447/001 28 film-coated tablets EU/1/08/447/002 84 film-coated tablets EU/1/08/447/005 14 film-coated tablets EU/1/08/447/006 42 film-coated tablets EU/1/08/447/007 56 film-coated tablets EU/1/08/447/008 98 film-coated tablets EU/1/08/447/013 14 film-coated tablets EU/1/08/447/014 28 film-coated tablets EU/1/08/447/015 42 film-coated tablets EU/1/08/447/016 56 film-coated tablets EU/1/08/447/017 84 film-coated tablets EU/1/08/447/018 98 film-coated tablets
Slovenian: EU/1/08/447/001 28 filmsko obloženih tablet EU/1/08/447/002 84 filmsko obloženih tablet EU/1/08/447/005 14 filmsko obloženih tablet EU/1/08/447/006 42 filmsko obloženih tablet EU/1/08/447/007 56 filmsko obloženih tablet EU/1/08/447/008 98 filmsko obloženih tablet EU/1/08/447/013 14 filmsko-obloženih tablet EU/1/08/447/014 28 filmsko-obloženih tablet EU/1/08/447/015 42 filmsko-obloženih tablet EU/1/08/447/016 56 filmsko-obloženih tablet EU/1/08/447/017 84 filmsko-obloženih tablet EU/1/08/447/018 98 filmsko-obloženih tablet
English: Population pharmacokinetic/pharmacodynamic analyses were conducted in 211 patients with hyperuricaemia and gout, treated with ADENURIC 40-240 mg QD.
Slovenian: Analize populacijske farmakokinetike/farmakodinamike so bile izvedene pri 211 bolnikih s hiperurikemijo in protinom, zdravljenih z zdravilom ADENURIC 40-240 mg enkrat na dan. Na splošno se parametri farmakokinetike febuksostata, ocenjeni v teh analizah, ujemajo s tistimi, ki so jih pridobili pri zdravih osebah, kar kaže, da so zdrave osebe ustrezne za oceno farmakokinetike/farmakodinamike pri bolnikih s protinom.
English: EU/1/08/447/003 28 film-coated tablets EU/1/08/447/004 84 film-coated tablets EU/1/08/447/009 14 film-coated tablets EU/1/08/447/010 42 film-coated tablets EU/1/08/447/011 56 film-coated tablets EU/1/08/447/012 98 film-coated tablets EU/1/08/447/019 14 film-coated tablets EU/1/08/447/020 28 film-coated tablets EU/1/08/447/021 42 film-coated tablets EU/1/08/447/022 56 film-coated tablets EU/1/08/447/023 84 film-coated tablets EU/1/08/447/024 98 film-coated tablets
Slovenian: EU/1/08/447/003 28 filmsko obloženih tablet EU/1/08/447/004 84 filmsko obloženih tablet EU/1/08/447/009 14 filmsko obloženih tablet EU/1/08/447/010 42 filmsko obloženih tablet EU/1/08/447/011 56 filmsko obloženih tablet EU/1/08/447/012 98 filmsko obloženih tablet EU/1/08/447/019 14 filmsko-obloženih tablet EU/1/08/447/020 28 filmsko-obloženih tablet EU/1/08/447/021 42 filmsko-obloženih tablet EU/1/08/447/022 56 filmsko-obloženih tablet EU/1/08/447/023 84 filmsko-obloženih tablet EU/1/08/447/024 98 filmsko-obloženih tablet
English: 46% and 38%, of patients on final stable treatment of febuxostat 80 or 120 mg QD, respectively, had complete resolution of the primary palpable tophus from baseline to the Final Visit.
Slovenian: Pri zaključnem obisku je bilo 46 % oziroma 38 % bolnikov stabilnih pri zdravljenju s febuksostatom 80 mg oziroma 120 mg enkrat na dan s popolnim razkrojem primarno tipljivega tofa.
English: (n=519) 1 results from subjects receiving either 100 mg QD (n=10: patients with serum creatinine >1.5 and ≤2.0 mg/dL) or 300 mg QD (n=509) were pooled for analyses.
Slovenian: (n=519) 1 za analize so bili zbrani podatki bolnikov, ki so prejemali bodisi 100 mg enkrat na dan (n=10: bolniki s serumskim kreatininom > 1,5 in  2,0 mg/dl) ali 300 mg enkrat na dan (n=509) * p < 0,001 v primerjavi z alopurinolom, # p < 0,001 v primerjavi z 80 mg
English: Febuxostat is a 2-arylthiazole derivative that achieves its therapeutic effect of decreasing serum uric acid by selectively inhibiting XO. Febuxostat is a potent, non-purine selective inhibitor of XO (NP-SIXO) with an in vitro inhibition Ki value less than one nanomolar.
Slovenian: Febuksostat je močan, nepurinski selektivni zaviralec ksantinske oksidaze (NP-SIXO) z vrednostjo zaviranja Ki in vitro manj kot en nanomol na liter.
English: NAME OF THE MARKETING AUTHORISATION HOLDER
Slovenian: Imetnik dovoljenja za promet:
English: In the post registrational CARES trial (see section 5.1 for detailed characteristics of the study) the rate of MACE events was similar in febuxostat versus allopurinol treated patients (HR 1.03; 95% CI 0.871.23), but a higher rate of cardiovascular deaths was observed (4.3% vs. 3.2% of patients; HR 1.34; 95% CI 1.03-1.73).
Slovenian: V preskušanju CARES iz obdobja trženja (glejte poglavje 5.1 za bolj podroben opis študije), je bila stopnja MACE (Major Adverse Cardiovascular Events) v skupini, ki je prejemala febuksostat podobna kot v skupini, ki je prejemala alopurinol (razmerje ogroženosti [HR - hazard ratio] 1,03; 95% interval zaupanja [IZ] 0,87-1,23), vendar je bil delež srčno-žilnih smrti večji v skupini zdravljeni s febuksostatom (4,3% v primerjavi z 3,2% bolnikov; HR 1,34; 95% IZ 1,03-1,73).
English: The ability of ADENURIC to lower serum uric acid levels was prompt and persistent.
Slovenian: Zdravilo ADENURIC je takoj in dolgotrajno znižalo vrednosti sečne kisline v serumu.
English: Pharmaprim AB Tlf: +468355933
Slovenian: Danmark Pharmaprim AB Tlf: +468355933